117 related articles for article (PubMed ID: 33112662)
21. A pan-cancer analysis based on weighted gene co-expression network analysis identifies the biomarker utility of lamin B1 in human tumors.
Hua Y; He Z; Zhang X
Cancer Biomark; 2022; 34(1):23-39. PubMed ID: 34511484
[TBL] [Abstract][Full Text] [Related]
22. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
[TBL] [Abstract][Full Text] [Related]
23. Association of plasma intermedin levels with progression and metastasis in men after radical prostatectomy for localized prostatic cancer.
Wang XL; Wang YY; He HD; Xie X; Yu ZJ; Pan YM
Cancer Biomark; 2015; 15(6):799-805. PubMed ID: 26406405
[TBL] [Abstract][Full Text] [Related]
24. Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort.
Jhun MA; Geybels MS; Wright JL; Kolb S; April C; Bibikova M; Ostrander EA; Fan JB; Feng Z; Stanford JL
Oncotarget; 2017 Jun; 8(26):43035-43047. PubMed ID: 28496006
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of SUMO-specific protease 1 (SENP1) in prostate cancer patients undergoing radical prostatectomy.
Li T; Huang S; Dong M; Gui Y; Wu D
Urol Oncol; 2013 Nov; 31(8):1539-45. PubMed ID: 23089540
[TBL] [Abstract][Full Text] [Related]
26. Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential.
Miller ET; You S; Cadaneanu RM; Kim M; Yoon J; Liu ST; Li X; Kwan L; Hodge J; Quist MJ; Grasso CS; Lewis MS; Knudsen BS; Freeman MR; Garraway IP
BMC Cancer; 2020 May; 20(1):398. PubMed ID: 32380981
[TBL] [Abstract][Full Text] [Related]
27. Differential Predictive Roles of A- and B-Type Nuclear Lamins in Prostate Cancer Progression.
Saarinen I; Mirtti T; Seikkula H; Boström PJ; Taimen P
PLoS One; 2015; 10(10):e0140671. PubMed ID: 26469707
[TBL] [Abstract][Full Text] [Related]
28. LMNB1, a potential marker for early prostate cancer progression.
Hong JH; Liang ST; Wang AS; Yeh CM; Huang HP; Sun CD; Zhang ZH; Lu SY; Chao YH; Chen CH; Pu YS
Am J Cancer Res; 2022; 12(7):3390-3404. PubMed ID: 35968338
[TBL] [Abstract][Full Text] [Related]
29. Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients.
Schmidt L; Fredsøe J; Kristensen H; Strand SH; Rasmussen A; Høyer S; Borre M; Mouritzen P; Ørntoft T; Sørensen KD
Ann Oncol; 2018 Sep; 29(9):2003-2009. PubMed ID: 30010760
[TBL] [Abstract][Full Text] [Related]
30. The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA.
Shi X; Zhang W; Nian X; Lu X; Li Y; Liu F; Wang F; He B; Zhao L; Zhu Y; Ren S; Sun Y
Int J Cancer; 2020 Jan; 146(2):475-486. PubMed ID: 31107971
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
[TBL] [Abstract][Full Text] [Related]
32. miR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma.
Xu S; Yi XM; Zhang ZY; Ge JP; Zhou WQ
Mol Med Rep; 2016 Dec; 14(6):5025-5032. PubMed ID: 27779679
[TBL] [Abstract][Full Text] [Related]
33. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
[TBL] [Abstract][Full Text] [Related]
34. TMEM45B is a novel predictive biomarker for prostate cancer progression and metastasis.
Luo F; Yang K; Wang YZ; Lin D
Neoplasma; 2018 Sep; 65(5):815-821. PubMed ID: 30249106
[TBL] [Abstract][Full Text] [Related]
35. Screening and identification of LMNB1 and DLGAP5, two key biomarkers in gliomas.
Zhou D; Wang M; Zhang Y; Wang K; Zhao M; Wang Y; Wang X; Yu R; Zhou X
Biosci Rep; 2021 May; 41(5):. PubMed ID: 33956061
[TBL] [Abstract][Full Text] [Related]
36. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease.
Kamoun A; Cancel-Tassin G; Fromont G; Elarouci N; Armenoult L; Ayadi M; Irani J; Leroy X; Villers A; Fournier G; Doucet L; Boyault S; Brureau L; Multigner L; Diedhiou A; Roupret M; Compérat E; Blanchet P; de Reyniès A; Cussenot O
Ann Oncol; 2018 Aug; 29(8):1814-1821. PubMed ID: 29945238
[TBL] [Abstract][Full Text] [Related]
38. A novel non-canonical Wnt signature for prostate cancer aggressiveness.
Sandsmark E; Hansen AF; Selnæs KM; Bertilsson H; Bofin AM; Wright AJ; Viset T; Richardsen E; Drabløs F; Bathen TF; Tessem MB; Rye MB
Oncotarget; 2017 Feb; 8(6):9572-9586. PubMed ID: 28030815
[TBL] [Abstract][Full Text] [Related]
39. Expression of KIF18A Is Associated with Increased Tumor Stage and Cell Proliferation in Prostate Cancer.
Zhang H; Shen T; Zhang Z; Li Y; Pan Z
Med Sci Monit; 2019 Aug; 25():6418-6428. PubMed ID: 31451680
[TBL] [Abstract][Full Text] [Related]
40. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
